Immune checkpoint was another important target for glioma treatment and some immunotherapy drugs had entered clinical trials, inhibition of PD‐L1, CTLA4, Indoleamine 2,3‐dioxygenase (IDO) was included.67 The gene discussed is IDO1; the disease is central nervous system cancer.